Key result
The combined baseline serum levels of SIRT1, ESM-1, and FGF21 strongly predicted treatment outcomes in patients with sepsis-related ARDS, yielding an area under the curve of 0.939.
Why the study?
The relationships among serum SIRT1, ESM-1, and FGF21 expression levels and treatment results in sepsis-associated ARDS needed investigation.
Observational (n=140)
Effect estimate: AUC 0.939
p-value: p=<0.05
The combination of serum SIRT1, ESM-1, and FGF21 levels provides high predictive value for treatment outcomes and correlates with disease severity in patients with sepsis-related ARDS.
Background: To investigate the relationships among the expression levels of serum silencing information regulator 2-related enzyme 1 (SIRT1), endothelial cell-specific molecule-1 (ESM-1), and fibroblast growth factor-21 (FGF21) and treatment results in patients with acute respiratory distress syndrome (ARDS) associated with sepsis. Methods: A total of 140 patients with sepsis-related ARDS were selected and divided into a good-outcome group (96 patients) and a poor-outcome group (44 patients) based on treatment outcome. The levels of serum SIRT1, ESM-1, and FGF21 were compared between the two groups; the correlations between serum SIRT1, ESM-1, and FGF21 and disease severity and treatment outcome were analysed; and the predictive value of serum SIRT1, ESM-1, and FGF21 for treatment outcomes was evaluated. Results: Compared with those in the group with favourable outcomes, the serum SIRT1 level was lower, while the ESM-1 and FGF21 levels were significantly higher in the poor outcome group than in the good outcome group (P<0.05). Serum SIRT1 levels decreased steadily in patients with mild, moderate, and severe illness, whereas ESM-1 and FGF21 levels increased consistently (P<0.05). ESM-1 and FGF21 showed a positive association with illness severity (P<0.05), whereas serum SIRT1 was negatively correlated (P<0.05) with disease severity according to Spearman correlation analysis. Partial correlation analysis indicated that serum SIRT1, ESM-1, and FGF21 levels were significantly related to treatment outcomes in patients with sepsis-related ARDS (P<0.05). The levels of serum SIRT1, ESM-1, and FGF21 and treatment outcomes were strongly linked (P<0.05) in patients with sepsis-related ARDS. The areas under the curve (AUCs) for predicting treatment course in patients with ARDS associated with sepsis were 0.742 for SIRT1, 0.838 for ESM-1, and 0.796 for FGF21. The sensitivities were 77.27% and 70.45%, and the specificities were 64.58%, 81.25%, and 87.50%, respectively. For patients with sepsis-related ARDS, the combined AUC of the three markers for treatment outcome was 0.939, with a sensitivity of 88.64% and a specificity of 83.33%, significantly surpassing the individual predictive values of the three markers alone (P<0.05). Conclusions: The levels of serum SIRT1, ESM-1, and FGF21 in patients with sepsis-related ARDS are strongly associated with both treatment efficacy and illness severity, can independently predict treatment outcomes, and have greater combined predictive value.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2025) conducted an observational in Sepsis-related acute respiratory distress syndrome (ARDS) (n=140). Serum SIRT1, ESM-1, and FGF21 levels was evaluated on Prediction of treatment outcome (poor vs. good) (AUC 0.939, p=<0.05). The combined baseline serum levels of SIRT1, ESM-1, and FGF21 strongly predicted treatment outcomes in patients with sepsis-related ARDS, yielding an area under the curve of 0.939.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: